<DOC>
	<DOC>NCT00141843</DOC>
	<brief_summary>The study will consist of two parts: a safety and efficacy period in which all subjects will participate and a pharmacokinetic analysis period, in which 30 eligible subjects will participate to compare ReFacto AF and Advate bioequivalency and safety and efficacy of ReFacto AF in patients with Hemophilia A.</brief_summary>
	<brief_title>Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Male subjects with severe or moderately severe hemophilia A A negative past medical history of a Factor VIII inhibitor Age greater than or equal to 12 years A history of Factor VIII inhibitors Presence of a bleeding disorder in addition to hemophilia Known hypersensitivity to hamster protein</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hemophilia A</keyword>
</DOC>